510-64-5
Chemical Structure
19-Hydroxyandrost-4-ene-3,17-dione
- CAS No.: 510-64-5
- Formula:C19H26O3
- Molecular Weight:302.41
IUPAC Name: (8R,9S,10S,13S,14S)-10-(hydroxymethyl)-13-methyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
InChIKey: XGUHPTGEXRHMQQ-BGJMDTOESA-N
SMILES: C[C@]1([C@](CC2)([H])[C@]3([H])CCC4=CC(CC[C@]4(CO)[C@@]3([H])CC1)=O)C2=O
Biological Activity: 19-Hydroxyandrost-4-ene-3,17-dione is an endogenous adrenal C19 steroid and also an agonist of the olfactory receptor OR51E2, with an EC50 of 0.15 nM. 19-Hydroxyandrost-4-ene-3,17-dione activates G protein-coupled receptor signaling pathways, drives neuroendocrine transdifferentiation, induces G0/G1 cell cycle arrest, reduces apoptosis and anabolic signaling, decreases cell viability, and reprograms cell metabolic profiles. 19-Hydroxyandrost-4-ene-3,17-dione induces sodium retention and hypertension, and its secretion is regulated by ACTH and the renin-angiotensin system. 19-Hydroxyandrost-4-ene-3,17-dione can be used in research related to prostate cancer, metastatic breast cancer, and hypertension[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
19-Hydroxyandrost-4-ene-3,17-dione | 99.11% | 19-Hydroxyandrost-4-ene-3,17-dione is an endogenous adrenal C19 steroid and also an agonist of the olfactory receptor OR51E2, with an EC50 of 0.15 nM. 19-Hydroxyandrost-4-ene-3,17-dione activates G protein-coupled receptor signaling pathways, drives neuroendocrine transdifferentiation, induces G0/G1 cell cycle arrest, reduces apoptosis and anabolic signaling, decreases cell viability, and reprograms cell metabolic profiles. 19-Hydroxyandrost-4-ene-3,17-dione induces sodium retention and hypertension, and its secretion is regulated by ACTH and the renin-angiotensin system. 19-Hydroxyandrost-4-ene-3,17-dione can be used in research related to prostate cancer, metastatic breast cancer, and hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Abaffy T, et al. A Testosterone Metabolite 19-Hydroxyandrostenedione Induces Neuroendocrine Trans-Differentiation of Prostate Cancer Cells an Ectopic Olfactory Receptor. Frontiers in oncology. 2018;8:162. [Content Brief]
- [2]. Sekihara H, et al. Angiotensin II induces the release of 19-hydroxyandrostenedione in man. The Journal of clinical endocrinology and metabolism. 1985 Aug;61(2):291-6.
